Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02185053 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia
A Phase 2 study, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02185053: Completed Phase 2 study, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
NCT02185053 is a Phase 2 study that has completed, run by Chase Pharmaceuticals Corporation, an affiliate of Allergan. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02185053, a Phase 2 study, has completed, sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
Primary Outcome
Number of participants who reached Donepezil Maximum Tolerated Dose of 40 mg/day (highest allowed per protocol) at the end of donepezil dose titration phase and at the end of the maintenance phase.
Interventions
- DRUG CPC-201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-07-31 |
| Est. Completion | 2016-07-31 |
| Phase | Phase 2 |
What the finished NCT02185053 record still lists
NCT02185053 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 1 intervention - of which CPC-201 is the first listed.
NCT02185053 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02185053 about?
NCT02185053 is a clinical study titled "A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia". This is a Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients with Alzheimer's Disease Type Dementia.
What is the current status of trial NCT02185053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2014-07-31. Estimated completion is 2016-07-31.
What interventions are being tested in trial NCT02185053?
The interventions under investigation include: CPC-201 (DRUG).
Who is sponsoring clinical trial NCT02185053?
This trial is sponsored by Chase Pharmaceuticals Corporation, an affiliate of Allergan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02185053's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI